MTX is a fully oxidised folic acid analogue extensively used in anti-cancer antifolate therapy, whose efficacy depends not only on its binding to the DHFR of rapidly dividing cancer cells, but also on its polyglutamylated forms binding to other enzymes in the folate pathway [45]. Here, DHFR is linked to cancer.